Patients’ characteristics in the cross-sectional cohort
| Characteristics . | All patients (N = 40) . | No relapse (n = 20) . | Relapse (n = 20) . | P . |
|---|---|---|---|---|
| Age at transplant, y | 52.5 [43-59] | 52.5 [45.5-60.5] | 52.5 [38.7-58.5] | 0.51 |
| Sex | .99 | |||
| Female | 21 (52) | 11 (55) | 10 (50) | |
| Male | 19 (48) | 9 (45) | 10 (50) | |
| ELN classification | .65 | |||
| Favorable | 5 (12,5) | 2 (10) | 3 (15) | |
| Intermediate | 18 (45) | 10 (50) | 8 (40) | |
| Adverse | 17 (42.5) | 8 (40) | 9 (45) | |
| Pretransplant treatments, n | .16 | |||
| 1 | 29 (72) | 17 (85) | 12 (60) | |
| ≥2 | 11 (28) | 3 (15) | 8 (40) | |
| Disease status at transplant | .10 | |||
| CR1 | 27 (67) | 17 (85) | 10 (50) | |
| CR ≥ 2 | 8 (20) | 2 (10) | 6 (30) | |
| No CR | 5 (13) | 1 (5) | 4 (20) | |
| Conditioning | .46 | |||
| Myeloablative | 9 (22,5) | 5 (25) | 4 (20) | |
| Nonmyeloablative | 3 (7.5) | 2 (10) | 1 (5) | |
| Reduced intensity | 25 (62,5) | 13 (65) | 12 (60) | |
| Sequential | 3 (7.5) | 0 (0) | 3 (15) | |
| Serotherapy | 32 (80) | 16 (80) | 16 (80) | .99 |
| Donor | .79 | |||
| Related | 19 (47.5) | 10 (50) | 9 (45) | |
| Matched unrelated | 18 (45) | 8 (40) | 10 (50) | |
| Mismatched unrelated | 3 (7.5) | 2 (10) | 1 (5) | |
| Stem cell source | .22 | |||
| Bone marrow | 2 (5) | 0 (0) | 2 (10) | |
| Peripheral blood | 37 (92,5) | 20 (100) | 17 (85) | |
| Umbilical cord blood | 1 (2.5) | 0 (0) | 1 (5) | |
| GVHD prophylaxis | .17 | |||
| CSA | 2 (5) | 0 (0) | 2 (10) | |
| CSA+MMF | 28 (70) | 13 (65) | 15 (75) | |
| CSA+MTX | 10 (25) | 7 (35) | 3 (15) | |
| Acute GVHD all grades | 14 (35) | 8 (40) | 6 (30) | .74 |
| Acute GVHD grade III/IV | 7 (17.5) | 4 (20) | 3 (15) | .99 |
| Chronic GVHD | 12 (30) | 9 (45) | 3 (15) | .08 |
| None | 2 (5) | 2 (22) | 0 (0) | |
| Moderate | 4 (10) | 3 (15) | 1 (5) | |
| Extensive | 6 (15) | 4 (20) | 2 (10) | |
| CMV reactivation | 7 (17.5) | 3 (15) | 4 (20) | .99 |
| Death | 22 (55) | 3 (15) | 19 (95) | <.0001 |
| Cause of death | ||||
| GVHD | 1 (2.5) | 1 (5) | 0 (0) | |
| Relapse | 18 (45) | 0 (0) | 18 (90) | |
| Secondary cancer | 1 (2.5) | 1 (5) | 0 (0) | |
| Toxicity | 1 (2.5) | 1 (5) | 0 (0) |
| Characteristics . | All patients (N = 40) . | No relapse (n = 20) . | Relapse (n = 20) . | P . |
|---|---|---|---|---|
| Age at transplant, y | 52.5 [43-59] | 52.5 [45.5-60.5] | 52.5 [38.7-58.5] | 0.51 |
| Sex | .99 | |||
| Female | 21 (52) | 11 (55) | 10 (50) | |
| Male | 19 (48) | 9 (45) | 10 (50) | |
| ELN classification | .65 | |||
| Favorable | 5 (12,5) | 2 (10) | 3 (15) | |
| Intermediate | 18 (45) | 10 (50) | 8 (40) | |
| Adverse | 17 (42.5) | 8 (40) | 9 (45) | |
| Pretransplant treatments, n | .16 | |||
| 1 | 29 (72) | 17 (85) | 12 (60) | |
| ≥2 | 11 (28) | 3 (15) | 8 (40) | |
| Disease status at transplant | .10 | |||
| CR1 | 27 (67) | 17 (85) | 10 (50) | |
| CR ≥ 2 | 8 (20) | 2 (10) | 6 (30) | |
| No CR | 5 (13) | 1 (5) | 4 (20) | |
| Conditioning | .46 | |||
| Myeloablative | 9 (22,5) | 5 (25) | 4 (20) | |
| Nonmyeloablative | 3 (7.5) | 2 (10) | 1 (5) | |
| Reduced intensity | 25 (62,5) | 13 (65) | 12 (60) | |
| Sequential | 3 (7.5) | 0 (0) | 3 (15) | |
| Serotherapy | 32 (80) | 16 (80) | 16 (80) | .99 |
| Donor | .79 | |||
| Related | 19 (47.5) | 10 (50) | 9 (45) | |
| Matched unrelated | 18 (45) | 8 (40) | 10 (50) | |
| Mismatched unrelated | 3 (7.5) | 2 (10) | 1 (5) | |
| Stem cell source | .22 | |||
| Bone marrow | 2 (5) | 0 (0) | 2 (10) | |
| Peripheral blood | 37 (92,5) | 20 (100) | 17 (85) | |
| Umbilical cord blood | 1 (2.5) | 0 (0) | 1 (5) | |
| GVHD prophylaxis | .17 | |||
| CSA | 2 (5) | 0 (0) | 2 (10) | |
| CSA+MMF | 28 (70) | 13 (65) | 15 (75) | |
| CSA+MTX | 10 (25) | 7 (35) | 3 (15) | |
| Acute GVHD all grades | 14 (35) | 8 (40) | 6 (30) | .74 |
| Acute GVHD grade III/IV | 7 (17.5) | 4 (20) | 3 (15) | .99 |
| Chronic GVHD | 12 (30) | 9 (45) | 3 (15) | .08 |
| None | 2 (5) | 2 (22) | 0 (0) | |
| Moderate | 4 (10) | 3 (15) | 1 (5) | |
| Extensive | 6 (15) | 4 (20) | 2 (10) | |
| CMV reactivation | 7 (17.5) | 3 (15) | 4 (20) | .99 |
| Death | 22 (55) | 3 (15) | 19 (95) | <.0001 |
| Cause of death | ||||
| GVHD | 1 (2.5) | 1 (5) | 0 (0) | |
| Relapse | 18 (45) | 0 (0) | 18 (90) | |
| Secondary cancer | 1 (2.5) | 1 (5) | 0 (0) | |
| Toxicity | 1 (2.5) | 1 (5) | 0 (0) |
Data are the number of patients (percentage of total group), unless stated otherwise. Boldface indicates significant values.
CMV, cytomegalovirus; CR, complete response; CSA, cyclosporine; ELN, European LeukemiaNet; MMF, mycophenolate mofetil; MTX, methotrexate.